Josh Kremer, MD, vice president of clinical development at Eisai, Inc, discusses results of the phase III SELECT trial, which studied lenvatinib in radioiodine-refractory differentiated thyroid cancer.
Josh Kremer, MD
Advertisement
Articles by Josh Kremer, MD
Advertisement
Latest Updated Articles
Lenvatinib Delays Thyroid Cancer ProgressionJuly 4th 2014
Advertisement
Advertisement
Trending on CancerNetwork
1
Frontline Sunvozertinib Improves PFS vs Chemotherapy in EGFR+ NSCLC
2
FDA Clears Investigator-Initiated IND for SRN-101 in Recurrent High-Grade Glioma
3
The Evolution of Artificial Intelligence in Oncology: Impact on Trials, Workflows, and Outcomes
4
Selinexor Combo Improves Spleen Volume Reduction in Myelofibrosis
5